Exelixis
EXEL
#1709
Rank
ยฃ9.34 B
Marketcap
ยฃ37.16
Share price
-0.58%
Change (1 day)
11.10%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): ยฃ2.33

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ2.33. In 2025 the company made an earnings per share (EPS) of ยฃ2.16.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)ยฃ2.337.92%
2025ยฃ2.16
2023ยฃ0.4914.61%
2022ยฃ0.43-22.97%
2021ยฃ0.55100%
2020ยฃ0.28-65.09%
2019ยฃ0.79-53.91%
2018ยฃ1.72333.96%
2017ยฃ0.40-260.61%
2016-ยฃ0.25-58.75%
2015-ยฃ0.60-42.45%
2014-ยฃ1.045.3%
2013-ยฃ0.98

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
ยฃ6.51 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ0.98-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ10.80 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ1.91-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ2.65 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ2.65 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
ยฃ2.90 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-ยฃ2.74-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-ยฃ0.63-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA